Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.90 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29435521 | 0.97 | MAPT (0.97) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL15141576 | 0.97 | MAPT (0.97) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL2722856 | 0.95 | MAPT (1.00) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL29437410 | 0.95 | MAPT (1.00) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL1393268 | 0.90 | MAPT (0.74) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL31073302 | 0.87 | MAPT (0.74) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL20676972 | 0.87 | MAPT (0.74) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL17055347 | 0.87 | POLB (0.89) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL5659915 | 0.87 | MAPT (0.74) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL2726097 | 0.85 | MAPT (0.72) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606556-B2 | TYK-2 inhibitor | BEONE MEDICINES I GMBH (CH) | 2026-04-21 | — | — | US | disclosed |
| CN-115003667-B | TYK-2 inhibitors | 百济神州有限公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2023213308-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 苏州隆博泰药业有限公司 | 2023-11-09 | — | — | WO | disclosed |
| US-20230159520-A1 | TYK-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159520-A1 | TYK-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159520-A1 | TYK-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| CN-115003667-A | TYK-2 inhibitors | 百济神州有限公司 | 2022-09-02 | — | — | CN | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
| US-8404848-B2 | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics | SANOFI (FR) | 2013-03-26 | — | — | US | disclosed |
| US-20100168155-A1 | DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-07-01 | — | — | US | disclosed |
| US-7704989-B2 | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-04-27 | — | — | US | disclosed |
| US-20090149441-A1 | DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606556-B2 | TYK-2 inhibitor | TYK2, TXK, JAK1 | MAPT 3485/4885POLB 2084/4885RAB9A 3431/4885 |
| US-20100168155-A1 | DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | NR4A2, NR4A3, NCOR1 | MAPT 4305/4885POLB 3617/4885RAB9A 3591/4885 |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | MAPT 1236/4885POLB 1657/4885RAB9A 3462/4885 |
| US-20090149441-A1 | DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | NR4A2, NR4A3, NCOR1 | MAPT 4305/4885POLB 3617/4885RAB9A 3591/4885 |
| US-20230159520-A1 | TYK-2 INHIBITOR | TYK2, IRAK2, PTK2B | MAPT 804/4885POLB 2307/4885RAB9A 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.